Cargando…
Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
The short half‐life of coagulation factor IX (FIX) for haemophilia B (HB) therapy has been prolonged through fusion with human serum albumin (HSA), which drives the neonatal Fc receptor (FcRn)‐mediated recycling of the chimera. However, patients would greatly benefit from further FIX‐HSA half‐life e...
Autores principales: | Lombardi, Silvia, Aaen, Kristin H., Nilsen, Jeannette, Ferrarese, Mattia, Gjølberg, Torleif T., Bernardi, Francesco, Pinotti, Mirko, Andersen, Jan T., Branchini, Alessio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362221/ https://www.ncbi.nlm.nih.gov/pubmed/34109608 http://dx.doi.org/10.1111/bjh.17559 |
Ejemplares similares
-
Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua
por: Robinson, Mary M., et al.
Publicado: (2021) -
Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients
por: Kawano, Hiroyuki, et al.
Publicado: (2011) -
Extracellular Ca(2+) modulates ADP-evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activation
por: Jones, Sarah, et al.
Publicado: (2011) -
Effective estimation of correct platelet counts in pseudothrombocytopenia using an alternative anticoagulant based on magnesium salt
por: Schuff-Werner, Peter, et al.
Publicado: (2013) -
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
por: Westwood, John-Paul, et al.
Publicado: (2014)